Advertisement

Topics

ABEC and WuXi Biologics Company Profile

17:54 EST 19th January 2019 | BioPortfolio

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.


News Articles [616 Associated News Articles listed on BioPortfolio]

WuXi Biologics Collaborates with I-Mab to Develop Three BiSpecifics

WuXi Biologics formed a collaboration with I-Mab Biopharma to develop three bi-specific antibodies, using WuXi's proprietary WuXiBody™ Platform to discover, develop and commercialize the three a...

WuXi Biologics’ third site: First batch done, US client next

WuXi Biologics completed its first manufacturing project at its 200,000 sq. ft. facility in Wuxi City earlier this week.

WuXi Biologics' Chief Quality Officer Received Foreign Post Service Award from FDA

SHANGHAI, Sept. 17, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development...

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel ...

SHANGHAI, Dec. 9, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development a...

WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

SHANGHAI and DUNDALK, Ireland, Dec. 5, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics...

WuXi Biologics Announced Successful Completion of the First cGMP Run in MFG3

- One of the largest biologics clinical manufacturing facilities globally with 6 production lines which enable WuXi Biologics to complete 60 IND-enabling projects per year Read more...

WuXi Biologics partners with Inhibrx for GMP manufacturing of protein─based therapeutics

WuXi Biologics, a leading global open─access biologics technology platform company offering end─to─end solutions for biologics discovery, development and manufacturing, and Inhibrx, Inc, a bioph...

WuXi Biologics breaks ground on $240m manufacturing site near Beijing

Construction has started at WuXi Biologicsâ eighth drug substance manufacturing facility, which CEO Chris Chen says will enable the CDMO to âdevelop and manufacture biologics more cost effectivelyâ...

PubMed Articles [102 Associated PubMed Articles listed on BioPortfolio]

Considerations for implementing an informatics system to support biologics drug discovery.

A comprehensive, well-functioning and scientifically aware informatics environment is of the utmost importance in supporting effective drug discovery programs. However, implementing such a system can,...

Analysis on voluntary blood donation and associated factors in men who have sex with men in 3 cities in China.

To assess the prevalence of blood donation and associated factors in men who have sex with men (MSM) in China. Our observational study was conducted between January and August, 2017 in 3 cities: Guan...

Advanced formulations for Intranasal Delivery of Biologics.

The global biologics market has been ever increasing over the last decades and is predicted to top Euro 350 by 2020. Facing this scenario, the parenteral route of biologics administration as hitherto ...

Dose Increase beyond Labelled Dose of Biologics Is Associated With Incremental Pharmacy Costs: Results from a Real-World Study In the UK.

Evidence regarding dosing patterns of biologics among moderate to severe psoriasis patients and impact on costs in the United Kingdom (UK) is limited.

Dosing considerations for inhaled biologics.

The number of biologics in the therapeutic development pipeline is increasing including those delivered though inhalation (Morales, 2017; Fathe, 2016). Biologics comprise a broad variety of complex ma...

Clinical Trials [86 Associated Clinical Trials listed on BioPortfolio]

Serological Screening of Gastric Cancer in Wuxi Region

The purpose of this study is to determine whether detection of pepsinogen Ⅰand Ⅱ combined with Helicobacter pylori antibody, so-called ABC method , is fit on gastric cancer screening i...

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

The purpose of this study is to compare the efficacy of Biologics + Methotrexate with Biologics + Tacrolimus measured by the disease activity score 28 (DAS28) erythrocyte sedimentation rat...

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Companies [286 Associated Companies listed on BioPortfolio]

ABEC and WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...

ABEC Incorporated

ABEC designs and manufactures custom designed, turn-key manufacturing equipment for the pharmaceutical, bio-tech, animal health and food industries. Our products include fermentors, bio-reactors, clea...

WuXi PharmaTech (Cayman) Inc.

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused co...

WuXi PharmaTech, Ltd.

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused com...

WuXi AppTec

WuXi AppTec’s U.S. Manufacturing and Testing group provides a comprehensive range of integrated programs for biologics, advanced therapies and medical devices – along wi...

More Information about "ABEC and WuXi Biologics" on BioPortfolio

We have published hundreds of ABEC and WuXi Biologics news stories on BioPortfolio along with dozens of ABEC and WuXi Biologics Clinical Trials and PubMed Articles about ABEC and WuXi Biologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ABEC and WuXi Biologics Companies in our database. You can also find out about relevant ABEC and WuXi Biologics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...


Corporate Database Quicklinks



Searches Linking to this Company Record